Syndax Pharmaceuticals (SNDX) Non-Current Deffered Revenue (2015 - 2021)

Syndax Pharmaceuticals' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $10.9 million for Q2 2021.

• On a quarterly basis, Non-Current Deffered Revenue fell 12.25% year-over-year to $10.9 million in Q2 2021; TTM through Jun 2021 was $10.9 million, a 12.25% decrease from a year earlier, with the FY2020 full-year figure at $11.6 million, down 11.54% from the prior year.
• Non-Current Deffered Revenue eased to $10.9 million in Q2 2021 per SNDX's latest filing, from $11.2 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $16.8 million in Q4 2017 and bottomed at $10.9 million in Q2 2021.
• The 5-year median for Non-Current Deffered Revenue is $13.6 million (2017), against an average of $13.6 million.
• Across the five-year window, Non-Current Deffered Revenue grew 17.86% in 2017 and dropped 12.58% in 2018, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $16.8 million in 2017, then slipped by 12.58% to $14.6 million in 2018, then retreated by 10.35% to $13.1 million in 2019, then decreased by 11.54% to $11.6 million in 2020, then decreased by 6.52% to $10.9 million in 2021.
• Per Business Quant, the three latest SNDX Non-Current Deffered Revenue figures stand at $10.9 million (Q2 2021), $11.2 million (Q1 2021), and $11.6 million (Q4 2020).